CDH5 and Alzheimer disease: The mRNA expression level of VE-Cadherin exhibited a trend of downregulation in the AD group and the Lecanemab-treated group compared to the vehicle group organoids (Fig. 7E, right panel), suggesting a potential disruption of endothelial adherent junctions and vascular integrity.